1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. Wee1
  4. Wee1 Inhibitor

Wee1 Inhibitor

Wee1 Inhibitors (16):

Cat. No. Product Name Effect Purity
  • HY-10993
    Adavosertib
    Inhibitor 99.97%
    Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
  • HY-145817A
    RP-6306
    Inhibitor 99.65%
    RP-6306 ((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects.
  • HY-13925
    PD0166285
    Inhibitor 99.46%
    PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 exhibits an IC50 of 3.433 μM for Chk1.
  • HY-147054
    WEE1-IN-5
    Inhibitor 99.90%
    WEE1-IN-5 is a potent WEE1 inhibitor with an IC50 value of 0.8 nM. WEE1-IN-5 inhibits phospho-CDC2. WEE1-IN-5 abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. WEE1-IN-5 can be used for researching anticancer.
  • HY-145817
    (Rac)-RP-6306
    Inhibitor 99.72%
    (Rac)-RP-6306 (compound 181) is a potent Myt1 inhibitor with an IC50 of <10 nM. (Rac)-RP-6306 (compound 181) has anticancer effects.
  • HY-160530
    WEE1-IN-6
    Inhibitor
    WEE1-IN-6 (compound 110) is a orally active WEE1 inhibitor with an DC50 value of ≦ 100 nM. WEE1-IN-6 inhibits cell proliferation.
  • HY-103029
    Bosutinib isomer
    Inhibitor
    Bosutinib isomer is a ligand or inhibitor with high binding affinity for both Wee1 and Wee2, with Kd values of 43.7 ± 10.0 and 4.7 ± 2.3 nM, respectively.
  • HY-157443
    Myt1-IN-4
    Inhibitor
    Myt1-IN-4 (21) is an orally active and selective MYT1 inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity.
  • HY-145817B
    (R)-RP-6306
    Inhibitor 99.87%
    (R)-RP-6306 can be used for the research of Myt1 mediated diseases and kinds of cancer for slowing the progression of cancer. (R)-RP-6306 (IC50=1360nM) is less active than (S)-RP-6306 (IC50<10nM).
  • HY-145664
    Myt1-IN-1
    Inhibitor 98.99%
    Myt1-IN-1 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132).
  • HY-138239
    WEE1-IN-3
    Inhibitor 98.64%
    WEE1-IN-3 is a potent Wee1 kinase inhibitor with an IC50 of <10 nM. WEE1-IN-3 has anticancer activities.
  • HY-108343
    WEE1-IN-4
    Inhibitor 99.60%
    WEE1-IN-4 is a potent checkpoint Wee1 kinase inhibitor with an IC50 of 0.011 μM.
  • HY-122113
    PD173952
    Inhibitor
    PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a Ki of 8.1 nM. PD173952 induces apoptosis.
  • HY-145666
    Myt1-IN-3
    Inhibitor 99.14%
    Myt1-IN-3 is a potent Myt1 inhibitor with an IC50s of <10 nM (WO2021195782 A1, compound 95).
  • HY-145665
    Myt1-IN-2
    Inhibitor
    Myt1-IN-2 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28).
  • HY-13925A
    PD0166285 dihydrochloride
    Inhibitor
    PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1.